Lv12
92 积分 2025-03-13 加入
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
2小时前
已完结
Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer
3小时前
已完结
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: a review of current and investigational treatment for HR+/Her2- breast cancer
1天前
已完结
Tyrosine kinase 2 inhibitors in autoimmune diseases
23天前
已完结
Physiological parameters in laboratory animals and humans
1个月前
已完结
Qualification of impurities based on metabolite data
1个月前
已完结
Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development
1个月前
已完结
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
1个月前
已完结
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
2个月前
已完结
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
2个月前
已完结
皖公网安备34019202002308
